ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 736

Reduced Circulating Levels of Inorganic Pyrophosphate Are Associated with Ectopic Calcification in Scleroderma Spectrum Disorders

Vivien Hsu1, Naomi Schlesinger 2, Qiaoli Li 3 and John Varga 4, 1Rutgers- RWJ Medical School, SOUTH PLAINFIELD, NJ, 2Rutgers Health- RWJ Medical School, New Brunswick, NJ, 3Thomas Jefferson University, Philadelphia, PA, 4Northwestern University, Chicago,, IL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: calcinosis and pyrophosphate, Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Calcinosis cutis due to ectopic mineralization is a common and disabling complication of systemic sclerosis (SSc) that has poorly understood pathogenesis and no effective treatment.  Inorganic pyrophosphate (PPi)  is a key regulator of ectopic mineralization acting by inhibiting hydroxyapatite crystal growth (1,2).  Ectopic mineralization has been attributed to low PPi levels in several genetic disorders such as pseudoxanthoma elasticum, generalized arterial calcification of infancy, and arterial calcification due to CD73 deficiency (3).   Herein, we sought to test the hypothesis that reduced plasma PPi levels may be associated with SSc and play a pathogenic role in calcinosis.

Methods: Subjects meeting the 2013 ACR criteria for SSc (4) and age-matched controls without SSc were recruited from Rheumatology outpatient clinics for this IRB-approved study. Calcinosis was confirmed either by clinical criteria or by imaging.  Levels of PPi in platelet-free plasma were measured by enzymatic reaction using  14C-labeled uridine-diphosphoglucose as substrate (5).  Student T-test was used to compare mean PPi levels between control and SSc groups and linear regression to compare means between the 3 groups (control, SS-calcinosis and SSc-no calcinosis) with adjustment of potential confounders.

Results: We studied 33 subjects (19 control and 14 SSc, 5 of whom had SSc-calcinosis).  In the SSc cohort, 60% had limited cutaneous SSc, as did 4 of 5 subjects with SSc-calcinosis.   The mean disease duration (from non-Raynaud symptoms) was 18.7 (SD 8.7) years in SSc-calcinosis and 10.3 (SD 7.4) years in SSc-no calcinosis groups.

Figure 1 shows that the SSc cohort had significantly lower plasma levels of PPi (mean=2.25 uM vs 3.04uM, p=0.0083) compared to the control group (see Table 1, p for group difference= 0.0137).  After adjusting for sex, the highest mean PPi levels were seen in the control group and the lowest in the SSc-calcinosis group.

Conclusion: Our findings indicate PPi levels are significantly reduced in SSc patients with calcinosis.  The results suggest that PPi deficiency may be  due to genetic or environmental influences that may be important in the pathophysiology of calcinosis, and could serve as a biomarker of the ectopic mineralization process.  Larger clinical studies to confirm our findings are warranted.

References:

  1. Fleisch H. et al: Nature 1966; 212: 901
  2. Orris IR. et al: Curr Opin Pharmacol. 2016; 28:57
  3. Li Q. et al: Am J. Pathol. 2019; 189: 216
  4. Hoogen F. et al: Ann Rheum Dis 2013; 72:1747 and Arthritis Rheum. 2013; 65: 2737
  5. Li Q. et al: Cell Cycle 2014; 13: 2609


Disclosure: V. Hsu, None; N. Schlesinger, amgen, 2, horizon pharma, 5, IFM Therapeutics, 5, Mallinckrodt Pharmaceuticals, 5, Novartis, 5, olatec, 5, pfizer, 2, Selecta Biosciences, 5; Q. Li, None; J. Varga, None.

To cite this abstract in AMA style:

Hsu V, Schlesinger N, Li Q, Varga J. Reduced Circulating Levels of Inorganic Pyrophosphate Are Associated with Ectopic Calcification in Scleroderma Spectrum Disorders [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/reduced-circulating-levels-of-inorganic-pyrophosphate-are-associated-with-ectopic-calcification-in-scleroderma-spectrum-disorders/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduced-circulating-levels-of-inorganic-pyrophosphate-are-associated-with-ectopic-calcification-in-scleroderma-spectrum-disorders/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology